PravinUDugelMD

Ophthalmology • Phoenix, AZ

Retinal Disease

Physician

Join to view full profile

Are you Dr. Dugel?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Connect with colleagues in the same hospital or clinic
You already have 59 invites waiting!
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Office
1101 E Missouri Ave
Phoenix, AZ 85014
Phone+1 602-222-2221

Fax+1 602-266-2044
Is this information wrong?

Summary

Dr. Pravin Dugel, MD is a board certified ophthalmologist in Phoenix, Arizona. He is currently licensed to practice medicine in Arizona and California. He is affiliated with St. Joseph's Hospital and Medical Center, HonorHealth Scottsdale Osborn Medical Center, and HonorHealth Deer Valley Medical Center.

Education & Training

University of Southern California/LAC+USC Medical CenterResidency, Ophthalmology, 1988 - 1994
David Geffen School of Medicine at UCLAClass of 1988

Certifications & Licensure

AZ State Medical License 1994 - 2026
CA State Medical License 1990 - 2025
American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com
Fellow (FAAO) American Academy of Ophthalmology

Clinical Trials

Safety and Tolerability of MS-R001 in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy Start of enrollment: 2006 Sep 01
Completed
Phase 1
A Study of Strontium90 Beta Radiation With Lucentis to Treat Age-Related Macular Degeneration Start of enrollment: 2007 Apr 01
Unknown status
Phase 3
Safety and Tolerability Study of the Helical Intravitreal Triamcinolone Implant in Diabetic Macular Edema Start of enrollment: 2005 Jun 01
Completed
Phase 1
A Randomized, Multi-center, Phase II Study of the Safety, Tolerability and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema (the iDEAL Study) Start of enrollment: 2012 Feb 01
Terminated
Phase 2
A 3-Month Clinical Trial to Assess the Safety and Efficacy of the OZURDEX® Intraocular Implant in Patients With Diabetes Mellitus Start of enrollment: 2012 Nov 01
Completed
Phase 2
Topcon Endpoint Management Start of enrollment: 2012 Aug 01
Completed
Not Applicable
Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD) Start of enrollment: 2013 May 01
Completed
Phase 4
Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis™ in Patients With Wet AMD Start of enrollment: 2015 Jul 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

7 citations
A Randomized Controlled Trial of OPT-302, a VEGF-C/D Inhibitor for Neovascular Age-Related Macular Degeneration.
Timothy L Jackson, Jason Slakter, Marc Buyse, Kun Wang, Pravin U Dugel, Charles C Wykoff, David S Boyer, Michael Gerometta, Megan E Baldwin, Clare F Price> ;Ophthalmology. 2023 Jun 1
6 citations
Topical treatment of diabetic macular edema using dexamethasone ophthalmic suspension: A randomized, double-masked, vehicle-controlled study.
Einar Stefansson, Thorstein Loftsson, Michael Larsen, András Papp, Kai Kaarniranta, Marion R Munk, Pravin Dugel, Ramin Tadayoni> ;Acta Ophthalmologica. 2023 Feb 1
1 citations
Evaluation of cardiac parameters and other safety outcomes of brolucizumab treatment in patients with neovascular age-related macular degeneration.
Nadia Zakaria, Nicolas Guerard, Andres Emanuelli, Pravin Dugel, Jen Watts, Melissa Liew, Margarita Gekkieva, Markus Hinder> ;Pharmacology Research & Perspectives. 2022 Apr 1
4 citations
EFFECT OF RETINAL THICKNESS VARIABILITY ON VISUAL OUTCOMES AND FLUID PERSISTENCE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Post Hoc Analysis of the HAWK and H...
Pravin U Dugel, Chirag D Jhaveri, Usha Chakravarthy, Charles C Wykoff, Rishi P Singh, Robin Hamilton, Georges Weissgerber, Zufar Mulyukov, Frank G Holz> ;Retina. 2022 Mar 1
18 citations
Complement cascade inhibition in geographic atrophy: a review.
Dhaval Desai, Pravin U Dugel> ;Eye. 2022 Feb 1
2 citations
Capillary density and caliber as assessed by optical coherence tomography angiography may be significant predictors of diabetic retinopathy severity.
Sam Kushner-Lenhoff, Kaitlin Kogachi, Melissa Mert, Zhongdi Chu, Anoush Shahidzadeh, Neal V Palejwala, Jeremy Wolfe, Sujit Itty, Kimberly A Drenser, Antonio Capone Jr,...> ;Plos One. 2022 Jan 1
5 citations
Phase 1 Dose-Escalation Study of Plasma Kallikrein Inhibitor THR-149 for the Treatment of Diabetic Macular Edema.
Pravin U Dugel, Arshad M Khanani, Brian B Berger, Sunil Patel, Mitchell Fineman, Glenn J Jaffe, Petra Kozma-Wiebe, Jeffrey Heier> ;Translational Vision Science & Technology. 2021 Dec 1
9 citations
Phase 1 Study of THR-687, a Novel, Highly Potent Integrin Antagonist for the Treatment of Diabetic Macular Edema.
Arshad M Khanani, Sunil S Patel, Victor H Gonzalez, Suk J Moon, Glenn J Jaffe, John A Wells, Petra Kozma, Pravin U Dugel, Raj K Maturi> ;Ophthalmology Science. 2021 Sep 1
191 citations
HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
Pravin U. Dugel, Rishi P Singh, Adrian Koh, Yuichiro Ogura, Georges Weissgerber, Kinfemichael Gedif, Glenn J. Jaffe, Ramin Tadayoni, Ursula Schmidt-Erfurth, Frank G. Holz> ;Ophthalmology. 2021 Jan 1
87 citations
Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinic...
Arshad M. Khanani, Sunil S. Patel, Philip J. Ferrone, Aaron Osborne, Jayashree Sahni, Susanna Grzeschik, Karen Basu, Jason S. Ehrlich, Zdenka Haskova, Pravin U. Dugel> ;JAMA Ophthalmology. 2020 Sep 1
56 citations
Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical...
Jayashree Sahni, Pravin U. Dugel, Sunil S. Patel, Mark Chittum, Brian Berger, Marta del Valle Rubido, Shamil Sadikhov, Piotr Szczesny, Dietmar Schwab, Everson Nogoceke...> ;JAMA Ophthalmology. 2020 Sep 1
11 citations
Clinical comparison of 27-gauge and 23-gauge instruments on the outcomes of pars plana vitrectomy surgery for the treatment of vitreoretinal diseases.
Steve Charles, Allen C. Ho, Pravin U. Dugel, Chris D Riemann, Maria H. Berrocal, Sunil Gupta, Cody Hamilton, Dina Joy K. Abulon> ;Current Opinion in Ophthalmology. 2020 May 1
41 citations
Surgical Method for Implantation of a Biosynthetic Retinal Pigment Epithelium Monolayer for Geographic Atrophy: Experience from a Phase 1/2a Study.
Amir H. Kashani, Jeremy Uang, Melissa Mert, Firas M. Rahhal, Clement Chan, Robert L. Avery, Pravin U. Dugel, Sanford Chen, Jane Lebkowski, Dennis O. Clegg, David R. Hi...> ;Ophthalmology. Retina. 2020 Mar 1
24 citations
Relationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: A post hoc analysis of Protocol I data.
Srinivas R. Sadda, Joanna Campbell, Pravin U. Dugel, Nancy M. Holekamp, Szilard Kiss, Anat Loewenstein, Albert J. Augustin, Vanessa Shih, Xiaoshu Xu, Charles C. Wykoff...> ;Eye. 2020 Mar 1
Cost-effectiveness analysis of ocriplasmin versus watchful waiting for treatment of symptomatic vitreomacular adhesion in the US.
Arshad M. Khanani, Pravin U. Dugel, Julia A. Haller, Alan L. Wagner, Benedicte Lescrauwaet, Ralph Schmidt, Craig Bennison> ;Journal of Comparative Effectiveness Research. 2020 Jan 21
118 citations
Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration.
Quan Dong Nguyen, Arup Das, Diana V. Do, Pravin U. Dugel, André O. Gomes, Frank G. Holz, Adrian Koh, Carolyn K. Pan, Yasir J. Sepah, Nikhil Patel, Heather MacLeod, Pat...> ;Ophthalmology. 2020 Jan 17
28 citations
Phase 1 Study of OPT-302 Inhibition of Vascular Endothelial Growth Factors C and D for Neovascular Age-Related Macular Degeneration.
Pravin U. Dugel, David S. Boyer, Andrew N. Antoszyk, Nathan C. Steinle, Michael P. Varenhorst, Joel A. Pearlman, Mark C Gillies, Robert Finger, Megan E. Baldwin, Ian M...> ;Ophthalmology. Retina. 2020 Mar 1
1 citations
Reply.
Pravin U Dugel, Adrian Koh, Yuichiro Ogura, Glenn J Jaffe, Ursula Schmidt-Erfurth, David M Brown, Andre V Gomes, James Warburton, Andreas Weichselberger, Frank G Holz> ;Ophthalmology. 2019 Dec 1
24 citations
Economic Value of Anti-Vascular Endothelial Growth Factor Treatment for Patients With Wet Age-Related Macular Degeneration in the United States.
Karen Mulligan, Seth A. Seabury, Pravin U. Dugel, Jill F. Blim, Dana P. Goldman, Mark S. Humayun> ;JAMA Ophthalmology. 2020 Jan 1
139 citations
Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial
Jayashree Sahni, Sunil S. Patel, Pravin U. Dugel, Arshad M. Khanani, Chirag Jhaveri, Charles C. Wykoff, Vrinda S. Hershberger, Meike Pauly-Evers, Shamil Sadikhov, Piot...> ;Ophthalmology. 2019 Aug 1
68 citations
Innovative therapies for neovascular age-related macular degeneration
Hasenin Al-khersan, Rehan M. Hussain, Thomas A. Ciulla, Pravin U. Dugel> ;Expert Opinion on Pharmacotherapy. 2019 Jul 12
3 citations
PATIENT-REPORTED VISUAL FUNCTION FROM THE OCRIPLASMIN FOR TREATMENT FOR SYMPTOMATIC VITREOMACULAR ADHESION, INCLUDING MACULAR HOLE (OASIS) STUDY.
Calvin E. Mein, Pravin U. Dugel, Leonard Feiner, Kim Drenser, Daniel M. Miller, Matthew S. Benz, Esmeralda Meunier, Lionel Moro, Mitchell S. Fineman> ;Retina. 2020 Jul 1
473 citations
HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration
Pravin U. Dugel, Adrian Koh, Yuichiro Ogura, Glenn J. Jaffe, Ursula Schmidt-Erfurth, David M. Brown, André Marcelo Vieira Gomes, James Warburton, Andreas Weichselberge...> ;Ophthalmology. 2020 Jan 1
61 citations
Complement inhibition as a therapeutic strategy in retinal disorders
Enoch Kassa, Thomas A. Ciulla, Rehan M. Hussain, Pravin U. Dugel> ;Expert Opinion on Biological Therapy. 2019 Feb 11
39 citations
ASSOCIATION BETWEEN EARLY ANATOMIC RESPONSE TO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY AND LONG-TERM OUTCOME IN DIABETIC MACULAR EDEMA: An Independent Analysis...
Pravin U. Dugel, Joanna Campbell, Szilard Kiss, Anat Loewenstein, Vanessa Shih, Xiaoshu Xu, Nancy M. Holekamp, Albert J. Augustin, Allen C. Ho, Victor H. Gonzalez, Sco...> ;Retina. 2019 Jan 1
Join now to see all

Authored Content

Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular DegenerationJuly 2020
Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular DegenerationJuly 2020
Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular DegenerationJuly 2020
Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular DegenerationJuly 2020
Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular DegenerationJuly 2020
Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular DegenerationJuly 2020
Join now to see all

Press Mentions

IVERIC Bio, Inc. (NASDAQ:ISEE) Q4 2022 Earnings Call TranscriptMarch 3rd, 2023
IVERIC Bio, Inc. (ISEE) Q1 2022 Earnings Call TranscriptMay 4th, 2022
Iveric Bio Completes Patient Enrollment of GATHER2 Pivotal Clinical Trial of Zimura® Ahead of ScheduleJuly 26th, 2021
Join now to see all

Professional Memberships

American Academy of Ophthalmology - AAO
Fellow

Hospital Affiliations

St. Joseph's Hospital and Medical CenterPhoenix, Arizona
HonorHealth Scottsdale Osborn Medical CenterScottsdale, Arizona
HonorHealth Scottsdale Shea Medical CenterScottsdale, Arizona
HonorHealth Deer Valley Medical CenterPhoenix, Arizona